The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Open accessAbstract
In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional T cells are characterized by reduced proliferative capacity, decreased effector function, and overexpression of multiple inhibitory receptors. Due to the presence of various inhibitory signals in the complex tumor microenvironment, tumor-specific T cells have distinct dysfunction states. Therapeutic reactivation of tumor-specific T cells has yielded good results in cancer patients. Here, we review the hallmarks of T cell dysfunction in cancer. Also, we discuss the relationship between T cell dysfunction and cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–216 of 216
Xu, L., Yang, L., Yao, D., Wu, X., Li, J., Liu, X., Deng, L., Huang, C., Wang, Y., Li, D., et al. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.01.001 · Cited by 97
Delpoux, A., Lai, C.-Y., Hedrick, S. Μ., & Doedens, A. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618916114 · Cited by 92
The evolving role of T-bet in resistance to infection
Pritchard, G. H., Kedl, R. M., & Hunter, C. A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0145-4 · Cited by 92
L ‐Arginine deprivation impairs Leishmania major ‐specific T‐cell responses
Munder, M., Choi, B., Rogers, M. E., & Kropf, P. (2009) · European Journal of Immunology · doi:10.1002/eji.200839041 · Cited by 82
Mulligan, J. K., Rosenzweig, S. A., & Young, M. R. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b91c9c · Cited by 79
Wei, G., Ding, L., Wang, J., Hu, Y., & Huang, H. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0070-9 · Cited by 78
PD-1 expression conditions T cell avidity within an antigen-specific repertoire
Simon, S., Vignard, V., Florenceau, L., Dréno, B., Khammari, A., Lang, F., & Labarrière, N. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1104448 · Cited by 76
Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells
Zolov, S. N., Rietberg, S. P., & Bonifant, C. L. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.07.005 · Cited by 75
The Yin and Yang of Myeloid Derived Suppressor Cells
Budhwar, S., Verma, P., Verma, R., Rai, S., & Singh, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02776 · Cited by 75
Zhu, L., Kong, Y., Zhang, J., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Palmisiano, N. D., Wang, M., Jia, B., Bayerl, M. G., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0486-z · Cited by 72
Wu, X., Li, J., Connolly, E. M., Liao, X., Ouyang, J., Giobbie‐Hurder, A., Lawrence, D. P., McDermott, D. F., Murphy, G. F., Zhou, J. M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0385 · Cited by 71
Sprouty-2 regulates HIV-specific T cell polyfunctionality
Chiu, Y., Shan, L., Huang, H., Haupt, C., Bessell, C. A., Canaday, D. H., Zhang, H., Ho, Y., Powell, J. D., Oelke, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70510 · Cited by 57
Programmed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function
Araki, K., Youngblood, B., & Ahmed, R. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2013.78.019869 · Cited by 55
Wu, X., Giobbie‐Hurder, A., Connolly, E. M., Li, J., Liao, X., Severgnini, M., Zhou, J. M., Rodig, S. J., & Hodi, F. S. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440930 · Cited by 42
Drennan, S., D’Avola, A., Gao, Y., Weigel, C., Chrysostomou, E., Steele, A. J., Zenz, T., Plass, C., Johnson, P., Williams, A. P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.356 · Cited by 39
Shaping of Peripheral T Cell Responses by Lymphatic Endothelial Cells
Humbert, M., Hugues, S., & Dubrot, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00684 · Cited by 32
Cited by
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 548
T Cell Dysfunction and Exhaustion in Cancer
Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00017 · Cited by 385
“Meanwhile, the TME contains a variety of cell types and cytokines (Table 1) that take part in tumor progression, which could contribute to T cell dysfunction (Xia et al., 2019).”
BackgroundSelf-citationDong, L., Chen, C., Zhang, Y., Guo, P., Wang, Z., Li, J., Liu, Y., Liu, J., Chang, R., Li, Y., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.016 · Cited by 278
Self-citation
Metadata
- Authors
- Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-19
- Volume
- 10
- Pages
- 1719-1719
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2961584252
- Cited by
- 341
- References
- 216
- FWCI
- 15.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.